Diversity of Tregs
==================

Regulatory T cells (Tregs) are a specialized subpopulation of T cells that can control undesired immune responses. They play a central role in maintaining homeostasis within the immune system, including both innate and adaptive immune networks, and also regulate inflammatory processes as those seen with tissue injury, transplant rejection, and autoimmunity.

As Tregs can function in secondary lymphoid organs, as well as the periphery, specialized subsets with distinct molecular mechanisms have developed with respect to these differing microenvironments. The thymus-derived Treg (tTreg) or so-called natural Treg is the dominant form of Treg, and shows a high expression of the transcription factor forkhead box P3 (FoxP3), which is the master control gene of Treg function and Treg development in the thymus ([@B37]; [@B56]). FoxP3^+^ Treg can furthermore be induced from naïve conventional T cells (Tconv) in the presence of specific cytokines and low amounts of antigens in the periphery ([@B26]; [@B1]; [@B16]), to yield the so-called induced Treg (iTreg). However, only tTreg express a demethylated region within the FoxP3 promoter, which stabilizes their phenotype. Type 1 regulatory T cells (Tr1 cells) are another type of adaptive Treg produced in the periphery, which express FoxP3 weakly, or not at all, but secrete IL10 and express granzyme B to kill myeloid antigen-presenting cells ([@B35]; [@B49]). All these Treg can control the immune responses of different cell types with several specific, partially overlapping mechanisms.

Nevertheless, tissue-resident Treg express different phenotypes, chemokine receptors, and T-cell receptors (TCRs), depending on their tissue location. The characteristics of tissue-resident Tregs have been thoroughly reviewed elsewhere ([@B5]). Here, we summarize the phenotype and function of the best studied tissue resident Treg. Characteristics of Treg in skin, visceral adipose tissue (VAT), skeletal muscle tissue, and solid tumor in non-lymphoid tissues are briefly described in Table [1](#T1){ref-type="table"}. These Treg promote the tissue repair process through the control of immune responses of T cells and other immune cells infiltrating the tissue (Figure [1](#F1){ref-type="fig"}), but also through the regulation of some non-immune pathways. For example, VAT Treg express peroxisome proliferator-activated receptor gamma (PPAR-*γ*), which is mainly present in adipocytes as a "master regulator" of their differentiation and glucose metabolism. VAT Treg can also activate the scavenger receptor CD36 expression to take-up lipids and promote adipogenesis, and PPAR-*γ* also interacts with FoxP3 to up-regulate Treg signature *in vitro* ([@B14]). In skeletal muscle, [@B6] found that a distinct Treg population can potentiate the muscle repair process through expression of the epidermal growth factor amphiregulin, which acts directly on muscle satellite cells *in vitro* and improves muscle repair *in vivo* in mice.

###### 

**Tissue resident Treg express different phenotype and function in different tissues**.

  **Resident tissue**                  **% of local resident CD4 T cells**   **Treg phenotype and characteristics**                                                                              **Treg function**                                                                                                                                                                                              **Reference**
  ------------------------------------ ------------------------------------- ------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------
  Skin                                 50--60%                               → Express effector-memory phenotype → Express CCR10                                                                 → Control inflammation and keep immune homeostasis in skin                                                                                                                                                     [@B80]
  Visceral adipose tissue (VAT)        \>50%                                 → Express CCR1, CCR2, CCR9 → Secrete IL10 → Distinct TCR with lymphoid-organ Treg → Express PPAR-*γ* Express CD36   → Control CD4 and CD8 Tconv in adipose tissue → Control co-resident pro-inflammatory macrophages and monocytes → Regulate adipocyte differentiation and promote Treg survival and frequency → Take up lipids   [@B25], [@B14]
  Skeletal muscle                      50--60%                               → Up-regulate IL10 production → Express amphiregulin → Skewed TCR different with muscle Tconv TCR                   → Control the switch of pro-inflammatory to anti-inflammatory response in injured muscle → Act directly on muscle satellite cells and improve muscle repair                                                    [@B5],[@B6])
  Solid tumor in non-lymphoid tissue   30--50%                               → Highly express CCR10, CTLA-4 → Secrete immune suppressive cytokines IL10 and TGF-β                                → On immune targets: facilitate tumor growth → On non-immune targets: pro-angiogenic effect                                                                                                                    [@B22], [@B75]

![**Molecular mechanisms used by Treg for the suppression of immune cells**.](fphar-06-00184-g0001){#F1}

Homing and Accumulation of Tregs at Sites of Injury
===================================================

Tissue regeneration is not only influenced by Tregs residing within the injured tissue, but also by recruitment of Tregs to sites of injury, which can lead to a 30--60% increase in cell number compared to local resident CD4 T cells. This is counterintuitive, given that most circulating Treg in murine models express the phenotype of naïve or central-memory T cells, which can only home to lymphoid tissues via CD62L/CCR7. Nevertheless, mounting evidence has been published that Treg can promote the regeneration process directly in the tissue ([@B6]), potentially by homing facilitated by their heterogeneous expression of the naïve/memory marker CD45RA, and some homing receptors.

The recruitment of Treg from the periphery to various non-lymphoid tissue is mainly associated with the following consecutive/overlapping issues:

1.  Expression of chemokine receptors on Treg, like CCR6, CXCR3, CCR4, CCR7, and CCR10 that support attraction of Treg to the specific tissues and execute rapid intra-tissue regulation ([@B33]; [@B20]; [@B13]). We recently demonstrated that about 10% Treg in the peripheral blood of healthy donors and patients awaiting for kidney transplantation express an effector-memory phenotype (CD45RA^--^CD62L^--^) allowing migration into inflamed tissues without further activation (Figure [2A](#F2){ref-type="fig"}). Upon *in vitro* expansion, a significant proportion of both naïve (CD45RA^+^CD62L^+^) and central-memory (CD45RA^--^CD62L^+^) Treg shift their phenotype into effector-memory like (Figure [2B](#F2){ref-type="fig"}), which could facilitate further migration of Treg into tissues when the expanded Treg products are transferred into patients ([@B43]).

![**A proportion of Treg express an effector-memory phenotype in healthy donors. (A)** Proportions of Treg subsets in total Treg in healthy donors (mean ± SD, *n* = 36, age 19--87 years). (B) A significant proportion of expanded naïve (TregN) and central-memory Treg (TregCM) converted into EM (CD45RA^--^CD62L^--^) phenotype upon 3 weeks of expansion with poly-clonal stimulation in the presence of rapamycin and interleukin 2. The mean frequency of cells expressing an EM phenotype is indicated for each cell type before and after expansion. (*n* = 5), paired *t*-test, taken from [@B43] \*\**p* \< 0.01.](fphar-06-00184-g0002){#F2}

1.  Exposure to tissue antigens can induce clonal expansion of Treg, which could result in the increase of intra-tissue Treg and bias of the TCR repertoire of Treg. Interestingly, we also observed that effector-memory Treg express a biased and less polyclonal TCR repertoire in the peripheral blood as shown by next-generation sequencing (Table [2](#T2){ref-type="table"}; [@B43]). These data support the view that an (auto)antigen-driven expansion of memory-effector Treg can contribute to the control of intra-tissue inflammation/regeneration.

###### 

**Coverage of the TCR repertoire by the top 20 clones in each Treg subset repertoire as shown by next-generation sequencing**.

  **Donor**                      **TregN (%)**    **TregCM (%)**     **TregEM (%)**
  ------------------------------ ---------------- ------------------ -------------------
  D1                             5.6              8.8                35.2
  D2                             2.9              15.7               38.5
  D3                             9.5              13.9               40.9
  D4                             2.7              8.1                30.3
  D5                             7.8              19.7               36.1
  Median (interquartile range)   5.6 (2.8--8.7)   13.9 (8.5--17.7)   36.1 (32.8--39.7)

1.  Exposure to tissue antigens in a tolerogenic environment can also induce naïve FoxP3^--^ Tconv to express FoxP3 and to become iTreg.

2.  The acquisition of the tissue-specific phenotype of tissue resident Treg can facilitate their adaption and survival ability in the tissue ([@B57]; [@B5]; [@B42]; [@B31]).

Interaction Between Tregs and Immune Cells
==========================================

Aside from the direct stimulatory effects of Tregs on tissue specific cells with regenerative properties (e.g., muscle satellite cells), Tregs can also impact tissue regeneration by modulation of local inflammation after injury. The molecular mechanisms that Treg use for the suppression of immune cells are shown in Figure [1](#F1){ref-type="fig"}. On one hand, Treg can secrete several immunosuppressive cytokines including transforming growth factor beta (TGFβ), IL10, and IL35 to control the immune responses. Treg are also reported to induce M2 macrophages, another key player in the tissue repair and regeneration, partly thorough IL10 and TGFβ pathway ([@B45]; [@B79]; [@B74]). On the other hand, Treg also express several important molecules to interact with other cells types and to counteract their activity (Figure [1](#F1){ref-type="fig"}):

1.  Tregs express high amounts of CD25, the *α*-chain of IL2 receptor, leading to IL2 consumption and thus inhibition of Tconv activation and proliferation ([@B3]; [@B19]).

2.  Tregs express CD39, an ectonucleotidase, that can facilitate the crosstalk between Treg and CD73-expressing cells to hydrolyze ATP ([@B63]; [@B85]), which is released into areas of tissue injury upon apoptosis of cells. The cleavage of ATP by Treg through the ectonucleotidase CD39 (ATP → ADP/AMP) and CD73 (AMP → Adenosine) would result finally in adenosine formation. Through adenosine receptor activation (primarily adenosine receptor A2A) and subsequent intracellular protein kinase A (PKA) activation by the second messenger cAMP, inhibitory pathways in inflammatory T cells and macrophages are triggered ([@B18]).

3.  Regarding the interactions of Treg with dendritic cells (DC) and B cells, Treg express high amounts of the inhibitory molecule cytotoxic T-Lymphocyte Antigen 4 (CTLA4), which competes for binding to CD80/CD86 with the co-stimulatory molecule CD28, thus decreasing the cross-talk between Tconv and antigen presenting cells *in vitro* and *in vivo*. In addition, Treg can also increase the expression of the enzyme indoleamine 2, 3-dioxygenase (IDO) in DCs via CTLA-4 induced signaling, resulting in starvation of Tconv and arrest of cell cycle, as IDO can catalyze degradation of the essential amino acid tryptophan, and also induces iTreg generation ([@B23]; [@B17]; [@B59]).

4.  Granzyme, another important molecule expressed by Treg, can facilitate the killing of responder cells in a perforin-dependent manner in human and mice ([@B34]; [@B30]). It is also reported that the restraint of NK cell cytotoxicity by Treg is related with both granzyme B-perforin dependent manner and the limiting of IL2 availability ([@B10]; [@B27]).

5.  The co-inhibitory molecule TIGIT, expressed by a distinct Treg population, specifically suppresses proinflammatory T helper 1 (Th1) and Th17 cell, but not Th2 cell responses ([@B38]).

6.  Treg can also induce target tissue cells to express molecules like heme oxygenase 1 (HO-1), an enzyme that degrades heme. Heme is released within post-trauma hematoma, and acts as a pro-inflammatory mediator through activation of toll-like receptor 4. Thus heme degradation can reduce the inflammation dramatically ([@B4]; [@B66]). Moreover, heme degradation further results in the formation of carbon monoxide, iron, and biliverdin, and these products also have cytoprotective and anti-inflammatory properties ([@B67]), which can protect endothelial cells to support angiogenesis as one of the first steps of successful tissue repair ([@B68]; [@B66]).

Thus, the interaction between Treg and immune cells can create an anti-inflammatory and anti-apoptotic immune environment to promote successful tissue repair.

Bone Tissue Regeneration
========================

As in other tissues, successful bone tissue repair depends on a multitude of tightly regulated immune and non-immune cells and signaling molecules. However, bone repair and regeneration is becoming increasingly popular as a topic of tissue regeneration studies, as bone is able to heal without scar formation. Better understanding of the interactions between immune and bone forming non-immune cells will continue to gain importance in an aging human population. Both the skeletal and the immune systems undergo changes with aging, affecting the specific cellular potential and the interaction of both systems ([@B81]). A deeper understanding of the positive aspects of Treg could be beneficial for the emerging therapeutic needs of an aging population. Thus, the new research crossfield of osteoimmunology, has been created in recent decades ([@B72]; [@B53]; [@B86]; [@B32]).

Mounting evidence has demonstrated that both adequate innate, and balanced adaptive immune responses are necessary for successful fracture repair, independently of any immune-related disease or infection ([@B41]; [@B55]; [@B69]), which implies a role for Tregs in bone regeneration.

The tissue healing process has been divided into several consecutive and overlapping processes, including inflammation, repair and remodeling ([@B41]; [@B61]). During the early phase of healing, when vessels are disrupted upon bone fracture, coagulation forms a hematoma, which is marked by low pH and hypoxia, a milieu not suitable for most cells. The hematoma includes the immune cells present in the blood upon clotting. These immune cells are adapted to survive under the difficult conditions and remain active ([@B7]), secreting large amounts of pro-inflammatory mediators, such as heme and cytokines like interferon gamma (IFN*γ*) and tumor necrosis factor alpha (TNF*α*; [@B68]; [@B67]; [@B4]; [@B66]). This pro-inflammatory reaction determines the beginning of the healing process ([@B41], [@B40]). However, the timely termination of this pro-inflammatory process is a prerequisite for the initiation of later regenerative phases such as angiogenesis and onset of endochondral ossification ([@B64]; [@B62]; [@B55]). Thus, the highly controlled pro-inflammatory and anti-inflammatory phases generated by the immune system are essential to create the appropriate conditions for successful bone tissue repair. For many years research on this topic focused on innate immunity only, however more recent data supports the important role of the adaptive immunity in regeneration as well.

Bone Homeostasis
================

Bone homeostasis is maintained by coordination between the processes of bone formation managed by osteoblasts (OBs), and bone resorption by osteoclasts (OCs). OCs derive from the monocyte-macrophage lineage under the effect of macrophage colony-stimulating factor (M-CSF) and receptor activator factor of nuclear factor *κ*B ligand (RANKL), which can bind with RANK on OCs precursors. This interaction can induce the fusion of OC precursors to form mature OCs. On the other hand, the bone forming cells, OBs are derived from the bone marrow mesenchymal stromal cells (MSCs) following different pathways involving several key transcription factors like Core-binding factor alpha1/Runt-related transcription factor 2 (Cbfa1/Runx2). Moreover, OBs can regulate the activity of OCs through expression of RANKL and osteoprotegerin (OPG), which can oppose the RANKL/RANK interaction ([@B51]). Balance between OBs and OCs is also heavily influenced by the immune system, mainly mediated by cytokines. Many immune cells, including T cells and B cells can produce RANKL to further promote the differentiation of OCs. Other pro-inflammatory cytokines like TNF*α*, interleukin 1 (IL1), IL6 and IL17 secreted by macrophages, T cells, natural killer cells, and neutrophils can also act on stromal cells to up-regulate the expression of RANKL and potentiate OCs differentiation. TNF*α* is the key player in the bone resorption as it can also inhibit the differentiation and bone-forming activity of OBs. The effect of IFN*γ* is rather weak in this process though it can also inhibit OC differentiation by down-regulation of TNF receptor-associated factor 6 (TRAF6). Additionally, the production of anti-inflammatory cytokines like IL4, IL10, IL35 and TGFβ by T cells, monocytes and different Treg can suppress synthesis of pro-inflammatory cytokines and inhibit OC differentiation. The effects of pro-inflammatory and anti-inflammatory cytokines on the differentiation of OBs and OCs are summarized in Table [3](#T3){ref-type="table"} ([@B32]; [@B51]; [@B24]).

###### 

**Pro- and anti-inflammatory cytokines secreted during tissue repair**.

  **Pro-inflammatory cytokines**   **Cellular sources (immune system)**                               **Effects on bone cells (bone resorption)**                                                                                                                                                                **Reference**
  -------------------------------- ------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------
  TNF*α*                           Macrophages, T cells, NK cells, neutrophils, mast cells, B cells   → Inhibit the differentiation and bone-forming activity of osteoblasts (OB) → Promote stromal cells to express RANKL for OC differentiation → Promote OC differentiation directly                          [@B12], [@B55]
  IL1, IL6                         T cells, macrophages, monocytes                                    Up-regulate RANKL to promote OC differentiation                                                                                                                                                            [@B32], [@B51]
  IL17                             T cells (Th17)                                                     → Acts on stromal cells and OB to up-regulate RANKL and OC differentiation                                                                                                                                 [@B48], [@B77]
  IFN*γ*                           NK cells, T cells                                                  → Inhibit OC differentiation by down-regulating TRAF6 → Indirectly effect TNF and RANKL expression → Block OB differentiation by inhibiting induction of RUNX2, a master regulator of OB differentiation   [@B73], [@B51]
  Anti-inflammatory cytokines      Cellular sources (immune system)                                   Major effect on bone cells (bone formation)                                                                                                                                                                
  IL4                              T cells (Th2), mast cells, B cells, stromal cells                  → Inhibit OC differentiation → Inhibition of LPS-induced pro-inflammatory cytokine synthesis → Positively influence OB migration                                                                           [@B82], [@B32], [@B60]
  IL10                             Monocytes, T cells, type 1 regulatory T cells                      → Inhibit monocyte/macrophage and neutrophil cytokine production → Inhibit Th1-type lymphocyte response → Block NF*κ*B pathway                                                                             [@B65]
  IL35                             Regulatory T cells, regulatory B cells                             → Suppress the proliferation of conventional T cells → Inhibit the differentiation of Th17 cells                                                                                                           [@B21], [@B70]
  TGFβ                             Constitutively expressed in many cell lines                        → Inhibit monocyte/macrophage MHC class II expression → Suppress proinflammatory cytokine synthesis MHC class II expression → Suppress pro-inflammatory cytokine synthesis                                 [@B60]

In addition, dual-specificity phosphatase 5 (DUSP-5) is a phosphatase that specifically dephosphorylates both phosphoserine and phosphotyrosine residues of MAPK to suppress its activity. The over expression of DUSP5 in splenic CD4 T cells can decrease the number of TH17 cells and increase the frequency of Treg in mouse by modulating their key transcriptional factor STAT3 and STAT5, which was related to inhibited ERK activity ([@B47]; [@B50]). These effects can further control exaggerated inflammation and facilitate the tissue repair process. DUSP-5 was also shown to down regulate pro-osteoclastogenic molecules like RANKL, RANK, NFATc1, thus playing an important role in keeping bone homeostasis ([@B50]).

Interaction Between Treg and Osteoclasts
========================================

So far osteoimmunology research has mostly focused on the interaction between Treg and OCs that are derived from the hematopoietic system. OCs are reported to function as antigen-presenting cells to activate CD4 T cells ([@B44]). Treg have been shown to suppress OC differentiation through cell-cell contact via CTLA4, though IL4 and TGF-β were also shown to be related, but not essential to the inhibitory effect on osteoclastogenesis *in vitro* ([@B39]; [@B82]; [@B2]). Meanwhile, protection of local and systematic bone destruction by Treg was observed *in vivo* ([@B83],[@B84]), indicating multiple levels of cross-talk between the skeletal and immune systems. Additionally, STAT5, an important transcriptional factor for Treg, might be another interesting modulator between OCs and Treg as it can negatively regulate the bone-resorbing function of OCs by promoting Dusp1 and Dusp2 expression ([@B36]). However, almost no data are available on OBs.

Possible Direct Interaction Between Treg and Osteoblasts and Their Precursors
=============================================================================

Consistent with the interactions of Treg with other tissue cells like adipocytes and muscle satellite cells, Treg may also directly interact with bone-forming cells or their progenitor cells, the MSCs. As MSCs are the progenitor cells for many tissue cells (e.g., OBs and adipocytes) and use very similar suppression mechanisms for immune responses as Treg, they might have more intensive interactions ([@B29]). Recently, many groups have reported that administration of MSCs can either increase the number and function of FoxP3^+^ Treg in a Jagged-1 dependent manner, or convert FoxP3^--^ Tconv into FoxP3^+^ Treg ([@B11]; [@B52]; [@B71]; [@B8]; [@B15]; [@B78]). However, the effect of Treg on MSCs is under-investigated. One group showed a positive effect on healing upon administration of combined Treg and bone marrow MSCs in a calvarial defect model in mice ([@B46]), although, the underlying molecular mechanisms have not been revealed.

It is known that both Treg and MSCs use the CD39--CD73-mediated adenosine-producing pathway to control inflammation. However, the dominant tTreg population mainly expresses CD39 (ENTPD1) rather than CD73 (NT5E), while bone marrow-derived MSCs mainly express CD73 rather than CD39 in human. We and others have shown that human Treg produce adenosine upon contact with CD73^+^ cells ([@B58]; [@B63]; [@B85]). Therefore, it is possible that Treg cooperate with MSCs to convert ATP into adenosine. The resulting adenosine can signal via 4 receptor subtypes: adenosine receptor A1 (ADORA1), ADORA2A, ADORA2B, and ADORA3. Undifferentiated bone marrow-derived MSCs mainly express ADORA2B. Various receptors are important for particular differentiation outcomes. ADORA2B is the essential receptor for MSCs differentiation into OBs, enabling bone formation, while ADORA1 and ADORA2A are more related with MSC differentiation toward adipocytes ([@B28]; [@B76]). Based on these facts, we hypothesize that Treg could act directly on OBs through coordination of the CD39--CD73-(adenosine)-ADOR pathway (Figure [3](#F3){ref-type="fig"}). This coordination regarding purinergic signaling may also exist between Treg and the tissue progenitor cells, which could potentiate the differentiation of MSCs and thus facilitate tissue regeneration. IDO and HO-1 induction by Treg on OBs may also be a result of direct cross-talk between Treg and OBs ([@B54]).

![**Hypothesized direct cross-talk between Treg and osteoblasts (MSCs).** (i) CD39 expressing Treg may co-operate with CD73 expressing osteoblasts (MSCs) to hydrolyze ATP to form adenosine, which can further bind to its receptor on osteoblasts (ADOR) to trigger the inhibitory pathways; (ii) Treg may up-regulate IDO and HO-1 expression on osteoblasts; (iii) Treg play a role in the balance of RANKL/OPG, thus facilitating osteoblast differentiation.](fphar-06-00184-g0003){#F3}

In addition, Treg may also play a role in regulating the ability of OBs to express RANKL and secrete OPG, influencing thereby the extent and degree of osteoclastogenesis. It is reported that expression of CD40L on activated CD4 T cells can induce the expression of RANKL and the suppression of secretion of OPG to facilitate osteoclastogenesis. However, Treg can inhibit CD40L expression on T cells very fast ([@B9]; [@B43]), thus the interaction between Treg and Tconv may regulate the RANKL/OPG balance to favor OB differentiation and bone formation. Nevertheless, Treg might also induce OPG production by OBs directly in some other manner. The hypothesized direct cross-talk between Treg and OBs (MSCs) are shown in Figure [3](#F3){ref-type="fig"}.

Summary or Outlook
==================

Taken together, Treg have been shown to be resident in various tissues, with specific phenotypes and functions. They create an anti-inflammatory and anti-apoptotic environment in these tissues through the control of undesired immune activities mainly caused by other immune cells, and thus facilitate the tissue repair and regeneration process indirectly. Here, we hypothesize possible direct cross-talk between Treg and OBs (MSCs), mainly through purinergic signaling, which might also potentiate the differentiation of MSCs, and facilitate bone regeneration. This hypothesis may provide a model for further investigations on the cross-talk between the immune and skeletal system, and enable the development of better strategies to promote bone repair and regeneration.
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